Base de datos : MEDLINE
Búsqueda : Hiperprolactinemia [Palabras]
Referencias encontradas : 2981 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 299 va a la página                         

  1 / 2981 MEDLINE  
              next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28246310
[Au] Autor:Oppelt PG; Müller A; Stephan L; Dittrich R; Lermann J; Büttner C; Ekici AB; Conzelmann G; Seeger H; Schöller D; Rall K; Beckmann MW; Strissel PL; Brucker SY; Strick R
[Ad] Dirección:Department of Gynecology and ObstetricsLaboratory of Molecular Medicine, University Hospital Erlangen, Erlangen, Germany.
[Ti] Título:Hyperandrogenemia and high prolactin in congenital utero-vaginal aplasia patients.
[So] Fuente:Reproduction;153(5):555-563, 2017 May.
[Is] ISSN:1741-7899
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Patients with the Mayer-Rokitansky-Küster-Hauser syndrome (MRKH) have a congenital utero-vaginal cervical aplasia, but normal or hypoplastic adnexa and develop with normal female phenotype. Some reports mostly demonstrated regular steroid hormone levels in small MRKH cohorts including single MRKH patients with hyperandrogenemia and a clinical presentationof hirsutism and acne has also been shown. Genetically a correlation of mutations with singular MRKH patients and hyperandrogenemia was noted. This study analyzed the hormone status of 215 MRKH patients by determining the levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, 17-OH progesterone, testosterone, dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG) and prolactin to determine the incidence of hyperandrogenemia and hyperprolactinemia in MRKH patients. Additional calculations and a ratio of free androgen index and biologically active testosterone revealed a hyperandrogenemia rate of 48.3%, hyperprolactinemia of 9.8% and combined hyperandrogenemia and hyperprolactinemia of 4.2% in MRKH patients. The rates of hirsutism, acne and especially polycystic ovary syndrome (PCOS) were in the normal range of the population and showed no correlation with hyperandrogenemia. A weekly hormone assessment over 30 days comparing 5 controls and 7 MRKH patients revealed high androgen and prolactin, but lower LH/FSH and SHBG levels with MRKH patients. The sequencing of , , and demonstrated no significant mutations correlating with hyperandrogenemia. Taken together, this study shows that over 52% of MRKH patients have hyperandrogenemia without clinical presentation and 14% hyperprolactinemia, which appeals for general hormone assessment and adjustments of MRKH patients.
[Mh] Términos MeSH primario: Anomalías Congénitas/fisiopatología
Hiperandrogenismo/etiología
Hiperprolactinemia/etiología
Anomalías Urogenitales/complicaciones
Útero/anomalías
Vagina/anomalías
[Mh] Términos MeSH secundario: Adulto
Femenino
Humanos
Hiperandrogenismo/diagnóstico
Hiperprolactinemia/diagnóstico
Pronóstico
Síndrome
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171031
[Lr] Fecha última revisión:171031
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170301
[St] Status:MEDLINE
[do] DOI:10.1530/REP-16-0408


  2 / 2981 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28236625
[Au] Autor:Overgaard M; Pedersen SM
[Ad] Dirección:.
[Ti] Título:Serum prolactin revisited: parametric reference intervals and cross platform evaluation of polyethylene glycol precipitation-based methods for discrimination between hyperprolactinemia and macroprolactinemia.
[So] Fuente:Clin Chem Lab Med;55(11):1744-1753, 2017 Oct 26.
[Is] ISSN:1437-4331
[Cp] País de publicación:Germany
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Hyperprolactinemia diagnosis and treatment is often compromised by the presence of biologically inactive and clinically irrelevant higher-molecular-weight complexes of prolactin, macroprolactin. The objective of this study was to evaluate the performance of two macroprolactin screening regimes across commonly used automated immunoassay platforms. METHODS: Parametric total and monomeric gender-specific reference intervals were determined for six immunoassay methods using female (n=96) and male sera (n=127) from healthy donors. The reference intervals were validated using 27 hyperprolactinemic and macroprolactinemic sera, whose presence of monomeric and macroforms of prolactin were determined using gel filtration chromatography (GFC). RESULTS: Normative data for six prolactin assays included the range of values (2.5th-97.5th percentiles). Validation sera (hyperprolactinemic and macroprolactinemic; n=27) showed higher discordant classification [mean=2.8; 95% confidence interval (CI) 1.2-4.4] for the monomer reference interval method compared to the post-polyethylene glycol (PEG) recovery cutoff method (mean=1.8; 95% CI 0.8-2.8). The two monomer/macroprolactin discrimination methods did not differ significantly (p=0.089). Among macroprolactinemic sera evaluated by both discrimination methods, the Cobas and Architect/Kryptor prolactin assays showed the lowest and the highest number of misclassifications, respectively. CONCLUSIONS: Current automated immunoassays for prolactin testing require macroprolactin screening methods based on PEG precipitation in order to discriminate truly from falsely elevated serum prolactin. While the recovery cutoff and monomeric reference interval macroprolactin screening methods demonstrate similar discriminative ability, the latter method also provides the clinician with an easy interpretable monomeric prolactin concentration along with a monomeric reference interval.
[Mh] Términos MeSH primario: Hiperprolactinemia/diagnóstico
Inmunoensayo/métodos
Inmunoensayo/normas
Prolactina/sangre
Prolactinoma/diagnóstico
[Mh] Términos MeSH secundario: Adolescente
Adulto
Anciano
Estudios de Casos y Controles
Precipitación Química
Intervalos de Confianza
Diagnóstico Diferencial
Femenino
Humanos
Masculino
Mediana Edad
Polietilenglicoles/química
Prolactina/inmunología
Prolactina/aislamiento & purificación
Prolactina/normas
Juego de Reactivos para Diagnóstico
Valores de Referencia
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Reagent Kits, Diagnostic); 30IQX730WE (Polyethylene Glycols); 9002-62-4 (Prolactin)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171030
[Lr] Fecha última revisión:171030
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170225
[St] Status:MEDLINE


  3 / 2981 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28780516
[Au] Autor:Chiloiro S; Giampietro A; Bianchi A; Tartaglione T; Capobianco A; Anile C; De Marinis L
[Ad] Dirección:Pituitary UnitDepartment of Endocrinology.
[Ti] Título:DIAGNOSIS OF ENDOCRINE DISEASE: Primary empty sella: a comprehensive review.
[So] Fuente:Eur J Endocrinol;177(6):R275-R285, 2017 Dec.
[Is] ISSN:1479-683X
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:Primary empty sella (PES) is characterized by the herniation of the subarachnoid space within the sella, which is often associated with variable degrees of flattening of the pituitary gland in patients without previous pituitary pathologies. PES pathogenetic mechanisms are not well known but seem to be due to a sellar diaphragm incompetence, associated to the occurrence of upper sellar or pituitary factors, as intracranial hypertension and change of pituitary volume. As PES represents in a majority of cases, a neuroradiological findings without any clinical implication, the occurrence of endocrine, neurological and opthalmological symptoms, due to the above describes anatomical alteration, which delineates from the so called PES syndrome. Headache, irregular menses, overweight/obesity and visual disturbances compose the typical picture of PES syndrome and can be the manifestation of an intracranial hypertension, often associated with PES. Although hyperprolactinemia and growth hormone deficit represent the most common endocrine abnormalities, PES syndrome is characterized by heterogeneity both in clinical manifestation and hormonal alterations and can sometime reach severe extremes, as occurrence of papilledema, cerebrospinal fluid rhinorrhea and worsening of visual acuity. Consequently, a multidisciplinary approach, with the integration of endocrine, neurologic and ophthalmologic expertise, is strongly advocated and recommended for a properly diagnosis, management, treatment and follow-up of PES syndrome and all of the related abnormalities.
[Mh] Términos MeSH primario: Enfermedades Asintomáticas
Síndrome de Silla Turca Vacía/diagnóstico
Encefalocele/diagnóstico
Hipófisis/diagnóstico por imagen
Silla Turca/diagnóstico por imagen
Espacio Subaracnoideo/diagnóstico por imagen
[Mh] Términos MeSH secundario: Síndrome de Silla Turca Vacía/diagnóstico por imagen
Síndrome de Silla Turca Vacía/fisiopatología
Síndrome de Silla Turca Vacía/terapia
Encefalocele/diagnóstico por imagen
Encefalocele/fisiopatología
Encefalocele/terapia
Hormona de Crecimiento Humana/deficiencia
Hormona de Crecimiento Humana/secreción
Humanos
Hiperprolactinemia/etiología
Hiperprolactinemia/prevención & control
Hipertensión Intracraneal/etiología
Hipertensión Intracraneal/prevención & control
Imagen por Resonancia Magnética
Neuroimagen
Papiledema/etiología
Papiledema/prevención & control
Hipófisis/fisiopatología
Hipófisis/secreción
Silla Turca/fisiopatología
Índice de Severidad de la Enfermedad
Espacio Subaracnoideo/fisiopatología
[Pt] Tipo de publicación:JOURNAL ARTICLE; REVIEW
[Nm] Nombre de substancia:
12629-01-5 (Human Growth Hormone)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171020
[Lr] Fecha última revisión:171020
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170806
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0505


  4 / 2981 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28763467
[Au] Autor:Wang ZL; Yang LY; Chen HH; Lin HH; Tsai YT; Huang WJ
[Ad] Dirección:Department of Physiology, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
[Ti] Título:Effects of TNF-α on penile structure alteration in rats with hyperprolactinemia.
[So] Fuente:PLoS One;12(8):e0181952, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:This study aimed to investigate the effects of anti-tumor necrosis factor (TNF)-α antibody (Ab) on alteration of penile structure in the hyperprolactinemia (hyperPRL) rat model. HyperPRL was induced in 8-week-old male Sprague-Dawley rats by allografting anterior pituitary (AP) glands under the renal capsule (+AP rats). Rats implanted with cerebral cortex (CX) were used as sham control (+CX rats). At 6 weeks post implantation, rats received either a single intra-testicular dose of TNF-α Ab (12.5 µg/kg) or testosterone replacement (2 doses of testosterone enanthate [TE], 3 mg/kg), and they were sacrificed 1 week later. Blood and penile tissue was collected for analysis. Compared to +CX rats, the +AP group had lower serum testosterone concentration and neuronal nitric oxide synthase (nNOS) expression, but exhibited a higher ratio of collagen III/I in the corpus cavernosum. Smooth muscle content exhibited no significant changes. At 1 week post TNF-α Ab injection, the collagen III/I ratio in the +AP group was decreased, and the smooth muscle content and nNOS expression increased significantly. These findings were comparable to those observed in +AP rats receiving TE. Testicular TNF-α suppresses testosterone release, which in turn results in the erectile dysfunction (ED) seen in hyperPRL. Intra-testicular TNF-α Ab treatment is as effective as testosterone supplementation on penile structure normalization in the hyperPRL model.
[Mh] Términos MeSH primario: Anticuerpos/farmacología
Hiperprolactinemia/sangre
Pene/patología
Factor de Necrosis Tumoral alfa/antagonistas & inhibidores
[Mh] Términos MeSH secundario: Animales
Corteza Cerebral/metabolismo
Colágeno/química
Disfunción Eréctil/fisiopatología
Macrófagos/metabolismo
Masculino
Músculo Liso/metabolismo
Óxido Nítrico Sintasa de Tipo I/metabolismo
Erección Peniana
Prolactina/sangre
Prolactina/metabolismo
Ratas
Ratas Sprague-Dawley
Testosterona/sangre
Testosterona/metabolismo
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Antibodies); 0 (Tumor Necrosis Factor-alpha); 3XMK78S47O (Testosterone); 9002-62-4 (Prolactin); 9007-34-5 (Collagen); EC 1.14.13.39 (Nitric Oxide Synthase Type I); EC 1.14.13.39 (Nos1 protein, rat)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171017
[Lr] Fecha última revisión:171017
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170801
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0181952


  5 / 2981 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28407622
[Au] Autor:Caponnetto S; Iannantuono GM; Barchiesi G; Magri V; Gelibter A; Cortesi E
[Ad] Dirección:Division of Medical Oncology, Department of Radiological, Oncological, and Pathological Sciences, "Sapienza" University of Rome, Rome, Italy.
[Ti] Título:Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
[So] Fuente:Oncology;93(1):62-66, 2017.
[Is] ISSN:1423-0232
[Cp] País de publicación:Switzerland
[La] Idioma:eng
[Ab] Resumen:BACKGROUND/AIMS: Prolactin (PRL) is a peptide hormone and several studies have demonstrated its role as a cytokine in human T cell-mediated immunity. We are unaware if PRL is a positive or negative immunomodulator, but its effects on the regulation of T cells could inhibit the antitumor activity elicited by nivolumab (NIVO). We aimed to assess whether the occurrence of hyperprolactinemia in metastatic non-small cell lung cancer (mNSCLC) patients treated with NIVO is associated with poor clinical outcomes. METHODS: We evaluated 26 mNSCLC patients treated with NIVO. Blood samples were collected in every patient to evaluate PRL basal levels before starting the therapy with NIVO and before each following administration of NIVO. All patients underwent a conventional CT to investigate the effect of therapy according to Immune-related Response Evaluation Criteria in Solid Tumors (IrRECIST). RESULTS: Twenty patients (77%) developed hyperprolactinemia during the treatment, whereas 6 patients (23%) had stable levels of PRL during the therapy (p = 0.001). A total of 95% of the 20 patients with hyperprolactinemia had progressive disease (PD), according to CT results, whereas only 2 patients (33%) out of 6 with stable PRL levels had PD (p = 0.004). CONCLUSIONS: Hyperprolactinemia in mNSCLC patients treated with NIVO could potentially represent a negative early predictive factor for poor clinical outcomes, thus anticipating PD shown by CT scan.
[Mh] Términos MeSH primario: Anticuerpos Monoclonales/uso terapéutico
Antineoplásicos/uso terapéutico
Carcinoma de Pulmón de Células no Pequeñas/quimioterapia
Hiperprolactinemia/sangre
Neoplasias Pulmonares/quimioterapia
Prolactina/sangre
[Mh] Términos MeSH secundario: Anciano
Anticuerpos Monoclonales/administración & dosificación
Anticuerpos Monoclonales/efectos adversos
Antineoplásicos/administración & dosificación
Antineoplásicos/efectos adversos
Biomarcadores de Tumor/sangre
Carcinoma de Pulmón de Células no Pequeñas/sangre
Carcinoma de Pulmón de Células no Pequeñas/inmunología
Carcinoma de Pulmón de Células no Pequeñas/patología
Femenino
Humanos
Hiperprolactinemia/etiología
Neoplasias Pulmonares/sangre
Neoplasias Pulmonares/inmunología
Neoplasias Pulmonares/patología
Masculino
Mediana Edad
Valor Predictivo de las Pruebas
Prolactina/secreción
Resultado del Tratamiento
[Pt] Tipo de publicación:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nombre de substancia:
0 (Antibodies, Monoclonal); 0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 31YO63LBSN (nivolumab); 9002-62-4 (Prolactin)
[Em] Mes de ingreso:1710
[Cu] Fecha actualización por clase:171018
[Lr] Fecha última revisión:171018
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170413
[St] Status:MEDLINE
[do] DOI:10.1159/000464328


  6 / 2981 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28904704
[Au] Autor:Barka I; Dendana E; Chikhrouhou N; Maroufi A; Kacem M; Chadli M; Ach K
[Ad] Dirección:Service d'Endocrinologie, CHU Farhat Hached de Sousse, Tunisie.
[Ti] Título:[Prolactin-secreting microadenoma in menopausal women].
[Ti] Título:Micro adénome à prolactine à l'âge de la ménopause..
[So] Fuente:Pan Afr Med J;27:177, 2017.
[Is] ISSN:1937-8688
[Cp] País de publicación:Uganda
[La] Idioma:fre
[Ab] Resumen:Prolactin-secreting adenoma is rare in elderly women. Patient's clinical picture may be confused with that of menopause, making diagnosis sometimes difficult. We report the case of a 57-year old woman with a 2-year history of secondary amenorrhea without hot flushes associated with galactorrhea in order to highlight the peculiarities of prolactin-secreting microadenomas. Physical examination confirmed the diagnosis of galactorrhoea and biology showed hyperprolactinemia at mIU/L, FSH = 15.1 IU/L and LH = 4,1 IU/L. Pituitary MRI showed left adenoma measuring 8 mm. Patient's evolution under dopaminergic treatment was marked by the recovery, for a transitional period, of mestrual cycles and the occurrence of hot flushes, normalization of prolactin levels and reduction of adenoma size.
[Mh] Términos MeSH primario: Adenoma/diagnóstico por imagen
Neoplasias Hipofisarias/diagnóstico por imagen
Prolactina/secreción
Prolactinoma/diagnóstico por imagen
[Mh] Términos MeSH secundario: Adenoma/patología
Adenoma/terapia
Amenorrea/diagnóstico
Amenorrea/etiología
Femenino
Galactorrea/diagnóstico
Galactorrea/etiología
Humanos
Hiperprolactinemia/etiología
Imagen por Resonancia Magnética
Menopausia
Mediana Edad
Neoplasias Hipofisarias/patología
Neoplasias Hipofisarias/terapia
Prolactinoma/patología
Prolactinoma/terapia
[Pt] Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nombre de substancia:
9002-62-4 (Prolactin)
[Em] Mes de ingreso:1709
[Cu] Fecha actualización por clase:170925
[Lr] Fecha última revisión:170925
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170914
[St] Status:MEDLINE
[do] DOI:10.11604/pamj.2017.27.177.11677


  7 / 2981 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28583458
[Au] Autor:Lin W; Gao L; Guo X; Wang W; Xing B
[Ad] Dirección:Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing, People's Republic of China; Peking Union Medical College, Beijing, People's Republic of China.
[Ti] Título:Xanthomatous Hypophysitis Presenting with Diabetes Insipidus Completely Cured Through Transsphenoidal Surgery: Case Report and Literature Review.
[So] Fuente:World Neurosurg;104:1051.e7-1051.e13, 2017 Aug.
[Is] ISSN:1878-8769
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Xanthomatous hypophysitis (XH) is extremely rare. Only 27 cases have been reported in the literature. No XH patient presenting with diabetes insipidus (DI) has been completely cured through surgery. Here, we describe the first XH case of a DI patient whose pituitary function was normalized postoperatively, without hormone replacement therapy. CASE DESCRIPTION: A 41-year-old woman suffered from polydipsia, DI, headache, and breast discharge. Laboratory investigation revealed hyperprolactinemia. Pituitary magnetic resonance imaging showed a 2.0-cm × 1.4-cm × 1.6-cm lesion that demonstrated heterogeneous intensity on T1-weighted imaging and peripheral ring enhancement following contrast; the lesion was totally removed through transsphenoidal surgery. Histopathologic and immunohistochemical examinations confirmed the diagnosis of XH. At the 4- and 15-month follow-up visits, all pituitary-related hormones were normal, and the patient was not taking medication. A repeat pituitary magnetic resonance imaging showed no evidence of recurrence. CONCLUSIONS: To the best of our knowledge, this case is the first documented occurrence of XH with DI completely cured through surgery. If XH is suspected, total surgical resection of the lesion is recommended and normal pituitary tissue should be carefully protected intraoperatively.
[Mh] Términos MeSH primario: Diabetes Insípida/cirugía
Hiperprolactinemia/cirugía
Hipofisitis/cirugía
Xantomatosis/cirugía
[Mh] Términos MeSH secundario: Adulto
Diabetes Insípida/etiología
Femenino
Humanos
Hiperprolactinemia/etiología
Hipofisitis/complicaciones
Hipofisitis/diagnóstico por imagen
Imagen por Resonancia Magnética
Neuroendoscopía
Xantomatosis/complicaciones
Xantomatosis/diagnóstico por imagen
[Pt] Tipo de publicación:CASE REPORTS; JOURNAL ARTICLE
[Em] Mes de ingreso:1709
[Cu] Fecha actualización por clase:170925
[Lr] Fecha última revisión:170925
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170606
[St] Status:MEDLINE


  8 / 2981 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28433845
[Au] Autor:Park HR; Kshettry VR; Farrell CJ; Lee JM; Kim YH; Won TB; Han DH; Do H; Nyguist G; Rosen M; Kim DG; Evans JJ; Paek SH
[Ad] Dirección:Department of Neurosurgery, Soonchunhyang University Seoul Hospital, Seoul, Korea; Department of Neurosurgery, Seoul National University Hospital, Seoul, Korea.
[Ti] Título:Clinical Outcome After Extended Endoscopic Endonasal Resection of Craniopharyngiomas: Two-Institution Experience.
[So] Fuente:World Neurosurg;103:465-474, 2017 Jul.
[Is] ISSN:1878-8769
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: The extended endoscopic endonasal approach (EEA) to the anterior cranial base is used for the resection of craniopharyngiomas. OBJECTIVE: We present clinical experience and outcomes of using EEA for craniopharyngiomas. METHODS: A total of 116 patients in 2 remote institutions were enrolled in this retrospective study. Surgical, endocrinologic, and ophthalmologic outcomes were assessed. RESULTS: The mean follow-up was 35 months (range, 1-115). Gross total resection (GTR), near total resection (NTR, >95%), and subtotal resection (STR) were achieved in 46%, 39%, and 15% of the patients, respectively. Surgery performed after 2010 was the only variable significantly associated with greater extent of resection, which might be explained by the learning curve. Overall tumor recurrence rate was 15.5%, with a median interval until recurrence of 14.5 months (range, 3-58). Extent of resection was significantly associated with recurrence-free survival (P = 0.0116). Those who underwent NTR/STR followed by adjuvant radiotherapy had a similar median recurrence-free survival rate compared with those who underwent GTR (26.5 vs. 20 months, P = 0.167). Endocrinologic examination revealed that 47.4% of patients experienced worsening of anterior pituitary function following surgery while 25.5% developed new-onset diabetes insipidus. Of the 89 patients with preoperative visual deficits, 68 (76.4%) experienced improvement in visual field assessment. CONCLUSION: EEA is effective for the surgical resection of craniopharyngiomas, resulting in high rates of visual improvement and low complication rates. Adjuvant radiotherapy is a useful method for tumor control after incomplete resection.
[Mh] Términos MeSH primario: Craneofaringioma/cirugía
Neuroendoscopía/métodos
Neoplasias Hipofisarias/cirugía
[Mh] Términos MeSH secundario: Adolescente
Adulto
Anciano
Craneofaringioma/complicaciones
Craneofaringioma/fisiopatología
Diabetes Insípida/epidemiología
Diabetes Insípida/etiología
Supervivencia sin Enfermedad
Femenino
Humanos
Hiperprolactinemia/etiología
Hipopituitarismo/epidemiología
Hipopituitarismo/etiología
Masculino
Mediana Edad
Cirugía Endoscópica por Orificios Naturales
Neoplasia Residual
Procedimientos Neuroquirúrgicos
Irradiación Hipofisaria
Neoplasias Hipofisarias/fisiopatología
Complicaciones Posoperatorias/epidemiología
Radioterapia Ayuvante
Estudios Retrospectivos
Resultado del Tratamiento
Trastornos de la Visión/etiología
Campos Visuales
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mes de ingreso:1709
[Cu] Fecha actualización por clase:170925
[Lr] Fecha última revisión:170925
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170423
[St] Status:MEDLINE


  9 / 2981 MEDLINE  
              first record previous record next record last record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:27773859
[Au] Autor:Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
[Ad] Dirección:Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
[Ti] Título:Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health.
[So] Fuente:World Neurosurg;97:595-602, 2017 Jan.
[Is] ISSN:1878-8769
[Cp] País de publicación:United States
[La] Idioma:eng
[Ab] Resumen:OBJECTIVE: In men with prolactinomas, impaired bone density is the principle consequence of hyperprolactinemia-induced hypogonadism. Although dopamine agonists (DAs) are the first-line approach in prolactinomas, surgery can be considered in selected cases. In this study, we aimed to investigate the long-term control of hyperprolactinemia, hypogonadism, and bone health comparing primary medical and surgical therapy in men who had not had prior DA treatment. METHODS: This is a retrospective case-note study of 44 consecutive men with prolactinomas and no prior DAs managed in a single tertiary referral center. Clinical, biochemical, and radiologic response to the first-line approach were analyzed in the 2 cohorts. RESULTS: Mean age at diagnosis was 47 years (range, 22-78 years). The prevalence of hypogonadism was 86%, and 27% of patients had pathologic bone density at baseline. The primary therapeutic strategy was surgery for 34% and DAs for 66% of patients. Median long-term follow-up was 63 months (range, 17-238 months). Long-term control of hyperprolactinemia required DAs in 53% of patients with primary surgical therapy, versus 90% of patients with primary medical therapy (P = 0.02). Hypogonadism was controlled in 73% of patients. The prevalence of patients with pathologic bone density was 37% at last follow-up, with no differences between the 2 therapeutic cohorts (P = 0.48). CONCLUSIONS: Despite control of hyperprolactinemia and hypogonadism in most patients independent of the primary treatment modality, the prevalence of impaired bone health status remains high, and osteodensitometry should be recommended.
[Mh] Términos MeSH primario: Enfermedades Óseas/mortalidad
Hiperprolactinemia/mortalidad
Hipogonadismo/mortalidad
Procedimientos Neuroquirúrgicos/utilización
Neoplasias Hipofisarias/mortalidad
Prolactinoma/mortalidad
Prolactinoma/terapia
[Mh] Términos MeSH secundario: Adulto
Anciano
Antineoplásicos/uso terapéutico
Enfermedades Óseas/prevención & control
Causalidad
Comorbilidad
Estudios de Seguimiento
Humanos
Hiperprolactinemia/prevención & control
Hipogonadismo/prevención & control
Incidencia
Estudios Longitudinales
Masculino
Salud del Hombre/estadística & datos numéricos
Mediana Edad
Procedimientos Neuroquirúrgicos/mortalidad
Neoplasias Hipofisarias/terapia
Factores de Riesgo
Tasa de Supervivencia
Suiza/epidemiología
Resultado del Tratamiento
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Antineoplastic Agents)
[Em] Mes de ingreso:1709
[Cu] Fecha actualización por clase:170911
[Lr] Fecha última revisión:170911
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:161024
[St] Status:MEDLINE


  10 / 2981 MEDLINE  
              first record previous record
selecciona
para imprimir
Fotocopia
Texto completo
[PMID]:28320371
[Au] Autor:Omi T; Ito H; Riku K; Kanai K; Takada H; Fujimi S; Matsunaga H; Ohi K
[Ad] Dirección:Department of Psychiatry, Osaka General Medical Center, Osaka, Japan. omi@gh.opho.jp.
[Ti] Título:Possible factors influencing the duration of hospital stay in patients with psychiatric disorders attempting suicide by jumping.
[So] Fuente:BMC Psychiatry;17(1):99, 2017 Mar 20.
[Is] ISSN:1471-244X
[Cp] País de publicación:England
[La] Idioma:eng
[Ab] Resumen:BACKGROUND: Patients with psychiatric disorders have a high rate of suicide. The present study investigated factors influencing hospital stays for Japanese patients with psychiatric disorders attempting suicide by jumping. METHODS: We diagnosed all suicide attempts (n = 113) by jumping based on the International Classification of Diseases 10th Revision (ICD-10) and investigated the mean hospital stays of patients with each diagnosis based on the ICD-10 code. We then analyzed differences in the demographic and clinical characteristics between the diagnostic groups to identify factors influencing the duration of hospital stay. RESULTS: Patients diagnosed with schizophrenia (F2 code) were the most frequent (32.7%) of all diagnoses; therefore, we divided the diagnostic groups into schizophrenia group (n = 37) and other psychiatric diagnoses group (n = 76). The patients with schizophrenia showed a significantly longer hospital stay (125.7 ± 63.9 days) compared with the patients with other psychiatric diagnoses (83.6 ± 63.2) (ß ± SE = 42.1 ± 12.7, p = 0.0013), whereas there was no difference in the jump height between the two groups (the average was the 3rd to 4th floor; p > 0.05). The number of injured parts, particularly lower-limb fractures, was significantly higher (p = 0.017) in patients with schizophrenia than in patients with other psychiatric diagnoses. The duration of psychiatric treatment in patients with schizophrenia were significantly longer (z = 3.4, p = 0.001) than in patients with other psychiatric diagnoses. CONCLUSION: Our findings indicate that the number of injuries and the body parts injured in patients with schizophrenia are associated with a longer duration of hospital stay following a suicide attempt by jumping. The current use of antipsychotics and a longer duration of taking antipsychotics might contribute to the risk of bone fracture via hyperprolactinemia. Further cognitive impairment in patients with schizophrenia might prevent rehabilitation for the management of lower-limb fractures. From these results, we suggest that clinicians should monitor the level of prolactin and cognitive function in patients with schizophrenia in future studies on managing of lower-limb fractures.
[Mh] Términos MeSH primario: Tiempo de Internación/estadística & datos numéricos
Trastornos Mentales/epidemiología
Trastornos Mentales/psicología
Esquizofrenia/epidemiología
Psicología del Esquizofrénico
Intento de Suicidio/psicología
Intento de Suicidio/estadística & datos numéricos
[Mh] Términos MeSH secundario: Adulto
Antipsicóticos/efectos adversos
Antipsicóticos/uso terapéutico
Femenino
Fracturas Óseas/inducido químicamente
Humanos
Hiperprolactinemia/inducido químicamente
Japón
Traumatismos de la Pierna/inducido químicamente
Masculino
Trastornos Mentales/quimioterapia
Mediana Edad
Estudios Retrospectivos
Factores de Riesgo
Esquizofrenia/quimioterapia
Heridas y Traumatismos/epidemiología
Heridas y Traumatismos/psicología
Adulto Joven
[Pt] Tipo de publicación:JOURNAL ARTICLE
[Nm] Nombre de substancia:
0 (Antipsychotic Agents)
[Em] Mes de ingreso:1708
[Cu] Fecha actualización por clase:170817
[Lr] Fecha última revisión:170817
[Sb] Subgrupo de revista:IM
[Da] Fecha de ingreso para procesamiento:170321
[St] Status:MEDLINE
[do] DOI:10.1186/s12888-017-1267-5



página 1 de 299 va a la página                         
   


Refinar la búsqueda
  Base de datos : MEDLINE Formulario avanzado   

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud